Antengene Corporation Limited recently participated in the Evercore 2nd China Biotech Summit, presenting significant updates on its research and development efforts. Key highlights included updated clinical data for its CLDN18.2 antibody-drug conjugate (ATG-022), demonstrating a promising objective response rate in patients with varying CLDN18.2 expression levels. Additionally, Antengene unveiled its proprietary TriGager™ T-cell engager (TCE) platform, showcasing its versatile engineering capabilities for treating various cancers and autoimmune diseases. The company also introduced ATG-207, a first-in-class bifunctional fusion protein aimed at T-cell mediated autoimmune conditions. Overall, Antengene continues to advance its clinical trials across multiple gastric cancer treatment lines while strengthening its TCE technology portfolio.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/healthcare/articles/antengene-presents-key-r-d-010000560.html
